About

The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP) was developed to accelerate the discovery of promising new diagnostic and progression biomarkers for Parkinson's Disease.
Who we are

Who we are

The Parkinson's Disease Biomarkers Program (PDBP) is made up of researchers, patients, family members, and healthcare professionals who are dedicated to accelerating the pace of biomarkers research.

What is a biomarker?

A biomarker, or biological marker, is a measurable attribute in a living person that indicates a disease, disease subtype, exposure, or risk. Examples of biomarkers for other diseases include cholesterol levels for heart disease and blood pressure for heart disease or stroke risk. No biomarkers currently exist for PD or related diseases.

The PDBP will serve as a multi-faceted platform for:

Integration

Integrating existing biomarker efforts

Standardization

Standardizing data collection and management across these efforts

Acceleration

Accelerating the discovery of new biomarkers

Collaboration

Fostering and expanding collaborative opportunities for all stakeholders

The PDBP has three major components

Projects We Support

Research Project

Funding supports discovery projects, designed to promote the identification of promising diagnostic and progression biomarkers.
Biorepositories

Biorepositories

Biospecimens are banked in biorepositories for processing, storage, and finally distribution for biomarkers research.
Data Management Resource

Data Management Resource

The DMR coordinates the assembly of de-identified data into a common database, enabling the query and distribution of aggregate data.

Interview with Dr. Walter Koroshetz, MD

Dr. Walter Koroshetz, MD, the director of the National Institute of Neurological Disorders and Stroke, answers some questions about the program during the 2018 PDBP All-hands event.

View All Videos